Abstract: The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol activation as well as uses thereof. Additionally, a method of treatment and prevention of a skin condition, an ocular disease or osteoarthritis is provided.

Abstract: The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol activation as well as uses thereof. Additionally, a method of treatment and prevention of a skin condition, an ocular disease or osteoarthritis is provided.

Abstract: A sterile hydrogel composition that includes a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 ?mol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 ?mol per gram polymer, and wherein the thiol-modified hyaluronan has a mean molecular weight of at least 400 kDa.

Abstract: A sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 ?mol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 ?mol per gram polymer, wherein the composition has a residual thiol content of less than 20% in respect to the degree of modification of the thiol-modified hyaluronan.

Abstract: The present invention relates to a sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer, for the specific use in the prevention or treatment of dry eye syndrome or dry eye signs and/or symptoms wherein said solution is applied prior to sleep.

Abstract: A method of preventing or treating an eye condition includes administering a sterile aqueous ophthalmic solution to an eye for the prevention or treatment of dry eye syndrome or dry eye sign and/or dry eye symptom. The sterile aqueous ophthalmic solution includes about 0.05% to about 0.5% (w/w) of N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer.

Abstract: The present invention relates to a sterile aqueous ophthalmic solution comprising N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer, for use in the treatment of corneal wounds.

Abstract: The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol activation as well as uses thereof. Additionally, a method of treatment and prevention of a skin condition, an ocular disease or osteoarthritis is provided.

Abstract: A method of preventing or treating an eye condition includes administering a sterile aqueous ophthalmic solution to an eye for the prevention or treatment of dry eye syndrome or dry eye sign and/or dry eye symptom. The sterile aqueous ophthalmic solution includes about 0.05% to about 0.5% (w/w) of N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer.

Abstract: The present invention is concerned with a sterile aqueous ophthalmic solution comprising about 0.05% to about 0.5% (w/w) of N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer. The invention is also concerned with a container containing said ophthalmic solution as well as the use thereof in the prevention or treatment of dry eye syndrome or dry eye signs and/or symptoms.

Abstract: The present invention relates to a sterile aqueous ophthalmic solution comprising N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer, for use in the treatment of corneal wounds.

Abstract: The present invention relates to a sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer, for the specific use in the prevention or treatment of dry eye syndrome or dry eye signs and/or symptoms wherein said solution is applied prior to sleep.

Abstract: The present invention is concerned with a sterile aqueous ophthalmic solution comprising about 0.05% to about 0.5% (w/w) of N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer. The invention is also concerned with a container containing said ophthalmic solution as well as the use thereof in the prevention or treatment of dry eye syndrome or dry eye signs and/or symptoms.

Abstract: A peristaltic pump for use in medical technology with a stator and a rotor. The stator 40 has an occlusion bed 12 which forms the contact area with a tube accommodated within, and the rotor is provided with rolling elements suitable for occluding a tube accommodated between the occlusion bed and the rolling elements. At least a part of the occlusion bed has an electrically conductive surface for reducing and/or preventing electrostatic charging of the tube. The stator may be injection molded from an electrically non-conductive plastic and the electrically conductive surface may be formed by a molded-in metallic insert or a molded-in metallic foil insert.

Abstract: The invention relates to a peristaltic pump for use in medical technology with a stator 40 and a rotor 20, whereby the stator 40 has an occlusion bed 12, which forms the contact area with a tube 30 accommodated within, and the rotor 20 is provided with rolling elements suitable for occluding a tube accommodated between the occlusion bed 12 and the rolling elements 24. The occlusion bed 12 thereby has at least in part an electrically conductive surface for reducing and/or preventing electrostatic charging of the tube 30.

Abstract: The present invention proposes an apparatus and a method for controlling the temperature of a dialysate, which is present in a dialysate container of a dialysate tank of a dialysis system, in a contact-free manner. It furthermore specifies a method for manufacturing such a dialysate container and system.

Abstract: By the reaction of chitosan with iminothiolactones such as 2-iminothiolane, thiol groups can be covalently immobilized on the polymer. The resulting chitosan derivatives exhibit thiol groups which are capable of forming inter- and intramolecular disulfide bonds. Because of this crosslinking process the viscosity of polymer solutions is strongly improved. Moreover, the cationic character of the polymer is strongly improved.

Abstract: By the reaction of chitosan with iminothiolactones such as 2-iminothiolane, thiol groups can be covalently immobilized on the polymer. The resulting chitosan derivatives exhibit thiol groups which are capable of forming inter- and intramolecular disulfide bonds. Because of this crosslinking process the viscosity of polymer solutions is strongly improved. Moreover, the cationic character of the polymer is strongly improved. Preferred applications of these novel chitosan derivatives are their cosmetic and pharmaceutical use.

Abstract: This invention relates to a pump (1) which is, in particular, constructed as an enclosed medical pump. To achieve an especially compact design, a pump section (6) which is connected to a rotor (5) of an electromagnetic drive means (2) for torque transmission is arranged inside said rotor (5) having a hollow interior.